Ascites

There are 50 papers on ascites in aging research: 3 trials and 34 observational studies in people, 3 in animals, 6 reviews. The newest story, Nov 7, 2026: “Drug use linked to better survival in a form of heart failure”.

Disease

50 papers study it50 more mention it10 findings

MeSH

7 new papers in 30 daysSee all 100 papers on ascites

“Exposure to GLP-1 RAs was associated with fewer cases of ascites (RD - 0.013; 95% CI - 0.014 to - 0.012; P < .001)”
Clinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction-associated steatohepatitis: A multinational cohort studyMedicine2026doi:10.1097/md.0000000000050733
  • Human trial3
  • Humans34
  • Animals3
  • In silico1

Interventions

1

Salt-restricted diet

downin humans1

1 study
  1. Salt-restricted diet is linked with lower ascites in cirrhotic patients with decompensated liver disease and grade III ascites (1.57 ± 0.65 vs. 4.07 ± 1.43 sessions/month, p < 0.001).

    “The SRD group showed better ascites control, with fewer paracentesis sessions per month (1.57 ± 0.65 vs. 4.07 ± 1.43, p < 0.001).”

    Humansin cirrhotic patients with decompensated liver disease and grade III ascitessix monthsn = 102

    Impacts of salt restriction on nutritional status, sarcopenia, and mortality of cirrhotic patients with ascites

    BMC gastroenterology

More on Salt-restricted diet

Associations

8

Frailty

upin humans2

2 studies
  1. Frailty is linked with a higher risk of ascites in humans (liver cirrhosis) (p < 0.001).

    “frailty was significantly associated with higher rates of ascites (p < 0.001), hepatic encephalopathy (p < 0.001), hepatorenal syndrome (p < 0.001), spontaneous bacterial peritonitis (p = 0.01)”

    Humansliver cirrhosis

    Prognostic Significance of Frailty in Liver Cirrhosis Patients: A Prospective Single-Center Study

    Journal of clinical medicine

  2. Ascites are associated with frailty in humans (liver cirrhosis).

    “Multiple linear regression analyses demonstrated that age, ascites and hepatic encephalopathy were positively associated with Frailty Index”

    Humansliver cirrhosisn = 355

    Health-related quality of life and frailty in liver cirrhosis

    BMJ supportive & palliative care

SGLT2 inhibitors

downin humans1HR 0.72

1 study
  1. SGLT2 inhibitors are associated with ascites in humans (alcoholic cirrhosis, type 2 diabetes, and obesity) (HR 0.72, 95% CI 0.67–0.77).

    “ascites (HR, 0.72; 95% CI, 0.67 to 0.77)”

    Humansalcoholic cirrhosis, type 2 diabetes, and obesity

    Sodium-glucose cotransporter-2 inhibitors and mortality and liver-related outcomes in patients with alcoholic cirrhosis, type 2 diabetes, and obesity

    Annals of hepatology

More on SGLT2 inhibitors

GLP-1 receptor agonists

downin humans1

1 study
  1. GLP-1 receptor agonists are linked with a lower risk of ascites in humans after 1:1 propensity score matching (RD -0.013 (95% CI -0.014 to -0.012)).

    “Exposure to GLP-1 RAs was associated with fewer cases of ascites (RD - 0.013; 95% CI - 0.014 to - 0.012; P < .001)”

    Humansafter 1:1 propensity score matchingn = 168,733

    Clinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction-associated steatohepatitis: A multinational cohort study

    Medicine

More on GLP-1 receptor agonists

Temsirolimus

upin humans1

1 study
  1. Temsirolimus is associated with ascites in humans (disproportionality signal in FAERS reports; not in drug label).

    “the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”

    Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929

    Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database

    Naunyn-Schmiedeberg's archives of pharmacology

More on Temsirolimus

Sarcopenia risk

upin humans1

1 study
  1. Ascites are associated with sarcopenia risk in patients with cirrhosis (aOR 1.87, 95% CI 1.18-2.95).

    “ascites (aOR: 1.87; 95% CI: 1.18-2.95) were independently associated with sarcopenia risk.”

    Humansin patients with cirrhosisn = 362

    Sarcopenia Risk Identified by Strength, Assistance With Walking, Rising From a Chair, Climbing Stairs, and Falls (SARC-F) in Patients With Cirrhosis: A Real-World Cross-Sectional Study

    Cureus

Sarcopenia

upin humans1

1 study
  1. Ascites are associated with sarcopenia in humans (bivariate analysis) (PR 1.606 (95% CI 1.110–2.324)).

    “ascites (PR = 1.606; 95% CI: 1.110-2.324; p = 0.034), and malnutrition (PR = 1.806; 95% CI: 1.242-2.626; p = 0.004) were associated with sarcopenia”

    Humansbivariate analysisn = 80

    The Association between Myostatin and Sarcopenia in Liver Cirrhosis

    Acta medica Philippina

More on Sarcopenia

Frailty

upin humans1

1 study
  1. Frailty is associated with ascites in patients on the liver transplant waiting list.

    “these studies have demonstrated that this population's frailty is associated with ascites, hepatic encephalopathy, and esophageal varices.”

    Reviewin patients on the liver transplant waiting list

    Frailty as a predictor of poor outcomes among patients awaiting liver transplant: a systematic review and meta-analysis

    Gastroenterology and hepatology from bed to bench

More on Frailty

Mortality

upin humans1HR 6.27

1 study
  1. Ascites are linked with a higher risk of mortality in Asian patients with cirrhosis (HR 6.27 (95% CI 1.6-24.1)).

    “Ascites (hazards ratio [HR] 6.27 [95% CI 1.6-24.1]; P < 0.007)”

    Humansin Asian patients with cirrhosisn = 219

    European Working Group on Sarcopenia in Older People (EWGSOP2) Criteria With Population-Based Skeletal Muscle Index Best Predicts Mortality in Asians With Cirrhosis

    Journal of clinical and experimental hepatology

Trial sponsors

Latest

Dec 2025: 1Jan 2026: 4Feb 2026: 8Mar 2026: 6Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 3Aug 2026: 1Sep 2026: 3Oct 2026: 4Nov 2026: 435 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Drug use linked to better survival in a form of heart failure

At 60 months, survival was 83.5% among users of glucagon-like peptide-1 receptor agonists, versus 57.4% among matched nonusers.At 60 months, survival was 83.5% among users of glucagon-like peptide-1 receptor agonists, versus 57.4% among matched nonusers.

Cohort studyPopulations
bioRxiv

Ovarian cancer grew and spread more in older mice

Experiments compared female mice aged 6–8 and 60–65 weeks; blocking a cell-signaling pathway in aged mice reduced cancer growth and spread.Experiments compared female mice aged 6–8 and 60–65 weeks; blocking a cell-signaling pathway in aged mice reduced cancer growth and spread.

Preprint: mouse studyOvarian cancer

See all 100 papers on ascites